



**GILEAD SCIENCES DENMARK APS
PATIENT ORGANISATION MEETING SPONSORSHIP AGREEMENT**

This sponsorship agreement (“**Agreement**”) is made effective as of the last date of signature below (the “**Effective Date**”) by and between

Gilead Sciences Denmark ApS, with a registered address of Gammel Kongevej 60, 1850 Frederiksberg C, Denmark (“**Gilead**”) and

HIV Danmark, with offices at SKINDERGRADE 44, 2, 1159 Copenhagen, CVR number 15921870 (“**Recipient**”).

1. Intent and independence of the parties. The receipt of support from Gilead, whether financial or otherwise, shall impose no obligation upon the Recipient to promote or otherwise encourage the prescription, recommendation, purchase, supply, sale or administration of the products of Gilead or its affiliates. The Recipient will not, and will not by Gilead be asked to, endorse any Gilead products.

No financial support provided under this Agreement will be conferred to pay or provide benefits for a government official or person who could influence the prescription, purchase or use of Gilead products, nor to otherwise gain a benefit for Gilead through improper influence.

2. Financial Support. Gilead hereby agrees to provide the Recipient the sum of DKK 32.220 (thirtytwo thousand twohundred and twenty) for the purpose of supporting “Orienteringsmøde 2023”. (“**Meeting**”). The financial support is provided based on the Recipient’s budget and agenda for the Meeting, as set out in Exhibit 1, and may only be used in compliance with Section 8. The amount may be adjusted if the Meeting is changed from a physical to virtual setting. The financial support is provided for and may only be used to cover the actual and necessary costs for the educational parts of the Meeting, e.g., costs for venue, speakers, material, moderate meals and/or other costs that may be supported by a pharmaceutical company under applicable laws and ethical rules.

For the purpose of transparency, and in return for the financial support, Gilead shall receive:

- Company logo on the program
- Free participation from company
- Booth size 3m2

3. Payment. The Recipient shall submit an invoice for the financial support for Gilead’s approval. The invoice is sent to intlapinvoices@gilead.com by email, or by regular mail to:

Gilead Sciences Denmark ApS
Lisa Stefanius
Little Island
PO Box 316
CO Cork
Ireland

The invoice shall include the below purchase order (“**PO**”) number: PO220002672

Gilead will make payments of the invoice within 30 working days of its receipt of the invoice to the bank account indicated by the Recipient on the invoice.

4. Declaration of use of Financial Support. Following the Meeting, the Recipient shall provide Gilead with a signed declaration warranting that the Meeting did not generate a surplus. The declaration shall be provided to Gilead within 6 months following the date of the Meeting. Any amounts exceeding the financial support provided by Gilead shall be paid back to Gilead, unless the parties agree otherwise.

5. Records. Gilead shall have a right to receive supporting documentation, such as invoices, relating to the Meeting, at any time, should Gilead so request.

6. Cancellation of Meeting. If the Meeting is cancelled, for whatever reason, the financial support shall be repaid to Gilead as soon as possible.

7. Public Disclosure. Gilead will be transparent about its support of the Recipient and the Recipient agrees to be similarly transparent.

The support and/or involvement of Gilead will be acknowledged by the Recipient and made clear on all materials (including the invitation to the Meeting) by using the following wording:

“Supported by Gilead Sciences Denmark ApS who provided funding. Gilead Sciences has had no input into the content of the materials and presentations used at this event”



To comply with applicable laws and rules, including the industry rules set out in the EFPIA Code and the Etisk nævn for lægemiddelindustrien (ENLI), Gilead will collect and publicly disclose information relating to Transfers of Value (as defined in the EFPIA Code), such as the Recipient's name and address, the fees paid by Gilead and the purpose of this Agreement ("Data"). Gilead will collect and publicly disclose Data via pages on the Gilead website and/or a central platform on the local industry association's website or that of another third party. Gilead will make disclosures of Data once annually in the first 6 months of each calendar year following the calendar year in which the Transfer of Value, to which the Data relates, was made. The Data will remain in the public domain for at least 3 years. Gilead shall be entitled to retain a record of the Data for at least 5 years.

In addition to what is stated above, Gilead may at its sole discretion decide to publicly disclose that it provides financial support to the Recipient. Any such disclosure will not include the specific financial amounts donated, unless required by local laws, regulations or codes of practice.

8. Compliance. The Meeting, and all activities and materials generated as a result of this relationship must comply with Danish laws and regulations relating to the provision of information on healthcare and medicinal products to the general public, including the EFPIA and the ENLI Code.

The Recipient may only use the financial support to sponsor the educational parts of the Meeting, e.g., venue, speakers, material and moderate meals during the Meeting. The financial support may not be used to finance the Recipient's day-to-day business or for other purposes, nor may it be used for providing gifts to attendees, recreational activities or

The parties hereto have entered into this Agreement as of the Effective Date by their duly authorised representatives.

GILEAD SCIENCES DENMARK APS

DocuSigned by:

Pascal Van Peborgh

209EF27F9DD4414.....

Name: Pascal Van Peborgh

Title: Nordic Medical Affairs Sen. Director

Date: 07 juli 2023

HIV DANMARK

DocuSigned by:

Jens Peder Høeberg

4A3025F68FC94A6.....

Name: Jens Peder Høeberg

Title: Chairman of Hiv-Danmark

Date: 07 juli 2023

entertainment of any kind to the meeting attendees. If the financial support is used for travel and/or accommodation for speakers or attendees (as allowed under applicable local codes), such travel shall be in economy class and shall be arranged so that the travel is made as close as possible to the opening of the Meeting and as close as possible to the end of the Meeting. The hospitality must be reasonable, suitable to the situation as well as secondary to the purpose of the Meeting.

Gilead will have the right to immediately terminate this Agreement for the breach of this Section, upon which the financial support shall be immediately refundable to Gilead.

9. Declaration. Both Gilead and the Recipient warrant to the other that the final form of this Agreement has been reviewed and approved by those with the necessary authority within Gilead and the Recipient.

10. General. This Agreement shall be governed by and construed in accordance with the laws of Denmark and the parties to this Agreement submit to the exclusive jurisdiction of the Danish courts as regards any claim, dispute or matter arising out of or relating to this Agreement.

This Agreement sets forth the complete, final and exclusive agreement between the parties and supersedes and terminates all prior agreements and understandings between the parties. No amendment to, or waiver of right under, this Agreement is effective unless in writing signed by authorized representatives of the parties.

Exhibit 1

AGENDA AND BUDGET

Orienteringsaften på Rigshospitalet

Hiv-Danmark inviterer til orienteringsaften i København
Torsdag 14. september 2023 på Rigshospitalet
Kl. 16.00 - 20.30
Adresse: Auditorium 2. ved opgang 2, Blegdamsvej 9, 2100 København Ø.

Arrangementet er gratis og åbent for alle hiv-positive, pårørende og andre med interesse for hiv.

PROGRAM

Kl. 16.00 **Markedsplads**

Boder med informationer vedrørende hiv

Kl. 17.00 **Velkomst og introduktion til aftenens program**

v/Hiv-Danmarks formand Jens Peder Høeberg

Kl. 17.10 **Medicinsk opdatering på hiv-behandlingen**

v/professor Jan Gerstoft

Kl. 17.45 **Psykosocial og seksuel sundhed hos personer der lever med hiv i Danmark**

v/seniorforsker Ellen Moseholm og ph.d.-studerende Ditte Scofield

Kl. 18.30 **Pause med kaffe, te og kage**

Markedspladsen er åben

Kl. 19.00 **Udfordringer for mennesker der lever med hiv – Hiv-Danmarks undersøgelser**

v/antropolog Anders Dahl

Kl. 19.35 **Ung med hiv: Kærlighed, karriere og stigma**

v/Marcus Beyer

Kl. 20.15 **Afslutning og opsummering på aftenens program**

Let traktement serveres efter programmet i personalekantin.

Hvis man er forhindret i at deltage fysisk på Rigshospitalet, kan mødet streames direkte via dette link: **XXX**

Tilmelding kan ske til info@hiv-danmark.dk

En særlig tak til Henning J. Sællænder for brug af hans kunstværk.

Tusind tak for støtten fra: **(Logo) MSD (Logo) GILEAD (Logo) ViiV**

Hiv-Danmark Orienteringsaften 14. september 2023 - budget**Donationer**

Gilead	32.220	
MSD	32.220	
GSK	32.220	
I alt	96.660	

Udgifter

Invitationer	3.350	
Porto	1.000	
Livestreaming	35.000	
Papirvarer	1.500	
Honorar referat	5.000	
Vin til forplejning 70 x 70	4.900	50750

Diverse til foyer og auditorium

Opsætning/afrydning i foyer og auditorium	500	
Buketter til markedsplads 10 x 200	2.000	
Vaser til markedsplads 10 x 25	250	
Roser til auditorium	300	3050

Udgifter på RH

Auditorie leje 7 x 600	4.200	
Operatør - blivende	2.500	
Forplejning i foyeren 100 x 35	3.500	
Forplejning i pausen 100 x 25	2.500	
Forplejning i personalekantin 100 x 175	17.500	30.200

Udgifter i alt **84000**

Administration 15 % af 84.000 12.600

Udgifter total **96600**

Certifikat for færdiggørelse

Kuvert-id: 8B36E96E10FA46A7B6BE899BB6A532AC

Status: Gennemført

Emne: Complete with DocuSign: FOR SIGNING_230914 HIVDanmark_Sponsorship Agr PAG (DENMARK) May 2022.pdf

Kildekuvert:

Dokumentsider: 5

Underskrifter: 2

Kuvertskaber:

Certifikatsider: 5

Initialer: 0

Lisa Stefanius

Autonavagation: Aktiveret

lisa.stefanius@gilead.com

Kuvertstempling: Aktiveret

IP-adresse: 24.206.103.24

Tidszone: (UTC-08:00) Pacific Time (US & Canada)

Sporing af poster

Status: Original

Ihændevarer: Lisa Stefanius

Sted: DocuSign

05-07-2023 05:57:13

lisa.stefanius@gilead.com

Hændelser for underskriver**Underskrift****Tidsstempel**

Pascal Van Peborgh

Pascal.vanPeborgh@gilead.com

Nordic Medical Affairs Sen. Director

Sikkerhedsniveau: E-mail, Kontogodkendelse
(ingen)

DocuSigned by:

Pascal Van Peborgh

309EF27F9DD411...

Sendt: 05-07-2023 06:03:37

Vist: 07-07-2023 04:31:56

Signeret: 07-07-2023 04:32:04

Vælg underskrift: Forudvalgt stil

Brug af IP-adresse: 24.206.103.24

Oplysninger om elektroniske poster og underskrifter:

Accepteret: 07-07-2023 04:31:56

Id: 47919e5b-e2b7-4996-a2aa-0c7e80e45f71

Jens Peder Høeberg

jens-peder@hiv-danmark.dk

Chairman of Hiv-Danmark

Sikkerhedsniveau: E-mail, Kontogodkendelse
(ingen)

DocuSigned by:

Jens Peder Høeberg

4A3025F63FC04A9...

Sendt: 07-07-2023 04:32:06

Vist: 07-07-2023 05:48:22

Signeret: 07-07-2023 05:55:59

Vælg underskrift: Forudvalgt stil

Brug af IP-adresse: 87.54.38.206

Oplysninger om elektroniske poster og underskrifter:

Accepteret: 07-07-2023 05:48:22

Id: 99607555-e406-497d-a2bb-768ee61a1467

Hændelser for personlig underskriver**Underskrift****Tidsstempel****Hændelser for redaktørlevering****Status****Tidsstempel****Hændelser for agentlevering****Status****Tidsstempel****Hændelser for midlertidig levering****Status****Tidsstempel****Hændelser for certificeret levering****Status****Tidsstempel****Hændelser for kopi (cc:)****Status****Tidsstempel**

Janniche Hammer

janniche.hammer@gilead.com

Director

Sikkerhedsniveau: E-mail, Kontogodkendelse
(ingen)**Kopieret**

Sendt: 07-07-2023 05:56:00

Oplysninger om elektroniske poster og underskrifter:

Accepteret: 17-05-2023 08:58:52

Id: 5fafbcd6-0b52-4c6c-b53a-81791c380ba4

Vidnehændelser**Underskrift****Tidsstempel**

Notarhændelser	Underskrift	Tidsstempel
-----------------------	--------------------	--------------------

Hændelser for kuvertoversigt	Status	Tidsstempler
-------------------------------------	---------------	---------------------

Kuvert sendt	Med hash/krypteret	05-07-2023 06:03:37
Leveret certificeret	Sikkerhedskontrolleret	07-07-2023 05:48:22
Signering fuldført	Sikkerhedskontrolleret	07-07-2023 05:55:59
Gennemført	Sikkerhedskontrolleret	07-07-2023 05:56:00

Betalingshændelser	Status	Tidsstempler
---------------------------	---------------	---------------------

Oplysninger om elektroniske poster og underskrifter
--

ELECTRONIC RECORD AND SIGNATURE DISCLOSURE

From time to time, Gilead Sciences Nordics (we, us or Company) may be required by law to provide to you certain written notices or disclosures. Described below are the terms and conditions for providing to you such notices and disclosures electronically through the DocuSign system. Please read the information below carefully and thoroughly, and if you can access this information electronically to your satisfaction and agree to this Electronic Record and Signature Disclosure (ERSD), please confirm your agreement by selecting the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

Getting paper copies

At any time, you may request from us a paper copy of any record provided or made available electronically to you by us. You will have the ability to download and print documents we send to you through the DocuSign system during and immediately after the signing session and, if you elect to create a DocuSign account, you may access the documents for a limited period of time (usually 30 days) after such documents are first sent to you. After such time, if you wish for us to send you paper copies of any such documents from our office to you, you will be charged a \$0.00 per-page fee. You may request delivery of such paper copies from us by following the procedure described below.

Withdrawing your consent

If you decide to receive notices and disclosures from us electronically, you may at any time change your mind and tell us that thereafter you want to receive required notices and disclosures only in paper format. How you must inform us of your decision to receive future notices and disclosure in paper format and withdraw your consent to receive notices and disclosures electronically is described below.

Consequences of changing your mind

If you elect to receive required notices and disclosures only in paper format, it will slow the speed at which we can complete certain steps in transactions with you and delivering services to you because we will need first to send the required notices or disclosures to you in paper format, and then wait until we receive back from you your acknowledgment of your receipt of such paper notices or disclosures. Further, you will no longer be able to use the DocuSign system to receive required notices and consents electronically from us or to sign electronically documents from us.

All notices and disclosures will be sent to you electronically

Unless you tell us otherwise in accordance with the procedures described herein, we will provide electronically to you through the DocuSign system all required notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you during the course of our relationship with you. To reduce the chance of you inadvertently not receiving any notice or disclosure, we prefer to provide all of the required notices and disclosures to you by the same method and to the same address that you have given us. Thus, you can receive all the disclosures and notices electronically or in paper format through the paper mail delivery system. If you do not agree with this process, please let us know as described below. Please also see the paragraph immediately above that describes the consequences of your electing not to receive delivery of the notices and disclosures electronically from us.

How to contact Gilead Sciences Nordics:

You may contact us to let us know of your changes as to how we may contact you electronically, to request paper copies of certain information from us, and to withdraw your prior consent to receive notices and disclosures electronically as follows:

To contact us by email send messages to: maria.wallin@gilead.com

To advise Gilead Sciences Nordics of your new email address

To let us know of a change in your email address where we should send notices and disclosures electronically to you, you must send an email message to us at maria.wallin@gilead.com and in the body of such request you must state: your previous email address, your new email address. We do not require any other information from you to change your email address.

If you created a DocuSign account, you may update it with your new email address through your account preferences.

To request paper copies from Gilead Sciences Nordics

To request delivery from us of paper copies of the notices and disclosures previously provided by us to you electronically, you must send us an email to maria.wallin@gilead.com and in the body of such request you must state your email address, full name, mailing address, and telephone number. We will bill you for any fees at that time, if any.

To withdraw your consent with Gilead Sciences Nordics

To inform us that you no longer wish to receive future notices and disclosures in electronic format you may:

- i. decline to sign a document from within your signing session, and on the subsequent page, select the check-box indicating you wish to withdraw your consent, or you may;
- ii. send us an email to maria.wallin@gilead.com and in the body of such request you must state your email, full name, mailing address, and telephone number. We do not need any other information from you to withdraw consent.. The consequences of your withdrawing consent for online documents will be that transactions may take a longer time to process..

Required hardware and software

The minimum system requirements for using the DocuSign system may change over time. The current system requirements are found here: <https://support.docusign.com/guides/signer-guide-signing-system-requirements>.

Acknowledging your access and consent to receive and sign documents electronically

To confirm to us that you can access this information electronically, which will be similar to other electronic notices and disclosures that we will provide to you, please confirm that you have read this ERSD, and (i) that you are able to print on paper or electronically save this ERSD for your future reference and access; or (ii) that you are able to email this ERSD to an email address where you will be able to print on paper or save it for your future reference and access. Further, if you consent to receiving notices and disclosures exclusively in electronic format as described herein, then select the check-box next to ‘I agree to use electronic records and signatures’ before clicking ‘CONTINUE’ within the DocuSign system.

By selecting the check-box next to ‘I agree to use electronic records and signatures’, you confirm that:

- You can access and read this Electronic Record and Signature Disclosure; and
- You can print on paper this Electronic Record and Signature Disclosure, or save or send this Electronic Record and Disclosure to a location where you can print it, for future reference and access; and
- Until or unless you notify Gilead Sciences Nordics as described above, you consent to receive exclusively through electronic means all notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you by Gilead Sciences Nordics during the course of your relationship with Gilead Sciences Nordics.